Fanconi Anemia Clinical Trials
Here are the 5 most popular medical studies for fanconi anemia
PARP Inhibitor
Olaparib for Biliary Tract Cancer
This trial is testing olaparib to treat patients with biliary tract cancer that has spread and who have aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Popular filter options for fanconi anemia trials
FA Clinical Trials
View 15 FA medical studies.
Monoclonal Antibodies
Stem Cell Transplant + JSP191 for Fanconi Anemia
This trial is testing an experimental cell therapy for Fanconi Anemia which may enable enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor after using an experimental treatment called JSP-191 as a part of conditioning.
FP-045 for Fanconi Anemia
This trial is testing a new drug, FP 045, to see if it is safe and works well in treating patients with Fanconi anemia who have not had a bone marrow transplant. The trial will enroll 14-18 patients, who will each receive the drug at 3 different dose levels for 28 days each.
Flavonoid
Quercetin for Squamous Cell Cancer in Fanconi Anemia
This trial is testing whether the supplement quercetin can prevent or delay the development of skin cancer in people with Fanconi anemia, a rare disease that leads to bone marrow failure and a higher risk for certain cancers.
Thrombopoietin Receptor Agonist
Eltrombopag for Fanconi Anemia
This trial is testing a new drug, eltrombopag, to see if it is effective in people with Fanconi anemia. People with the disease often have reduced blood cell counts and may need transfusions. The trial will monitor participants closely for side effects.
Fanconi Anemia Clinical Trials With No Placebo
View 15 fanconi anemia medical studies that do not have a placebo group.
Monoclonal Antibodies
Stem Cell Transplant + JSP191 for Fanconi Anemia
This trial is testing an experimental cell therapy for Fanconi Anemia which may enable enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor after using an experimental treatment called JSP-191 as a part of conditioning.
FP-045 for Fanconi Anemia
This trial is testing a new drug, FP 045, to see if it is safe and works well in treating patients with Fanconi anemia who have not had a bone marrow transplant. The trial will enroll 14-18 patients, who will each receive the drug at 3 different dose levels for 28 days each.
Flavonoid
Quercetin for Squamous Cell Cancer in Fanconi Anemia
This trial is testing whether the supplement quercetin can prevent or delay the development of skin cancer in people with Fanconi anemia, a rare disease that leads to bone marrow failure and a higher risk for certain cancers.
Thrombopoietin Receptor Agonist
Eltrombopag for Fanconi Anemia
This trial is testing a new drug, eltrombopag, to see if it is effective in people with Fanconi anemia. People with the disease often have reduced blood cell counts and may need transfusions. The trial will monitor participants closely for side effects.
Frequently Asked Questions
Introduction to fanconi anemia
What are the top hospitals conducting fanconi anemia research?
Fanconi anemia, a rare genetic disorder that affects bone marrow and increases the risk of cancer, has drawn the attention of several top hospitals conducting clinical trials. In Cincinnati, the Children's Hospital Medical Center is leading the charge with four active trials dedicated to fanconi anemia and a solid record of 10 completed studies since their first trial in 2004. Meanwhile, at the Masonic Cancer Center in Minneapolis, researchers are diligently working on two ongoing trials for this condition while having accomplished five previous investigations since initiating their first fanconi anemia trial in 2000.
In Stanford, California, both Stanford University and Lucille Packard Children's Hospital are making significant contributions to understanding and treating fanconi anemia. Stanford University currently hosts two active clinical trials for this disorder but has recorded only two all-time experiments thus far—although its pioneering efforts began as recently as 2020. Furthermore,Lucille Packard Children's Hospital made remarkable progress by launching their very first fanconi anemia trial in just three years from now; meanwhile they continue to push forward with one ongoing study focused on this challenging condition.
The M D Anderson Cancer Center based in Houston also joins these esteemed institutions with expertise in tackling fanconi anemia. They have conducted two all-time clinical trials for this rare genetic disease since recording their inaugural investigation back in 2007.Across different locations spanning from Ohio to Texas and Minnesota to California each hospital mentioned plays a crucial role not just within individual communities but collectively contributing towards scientific advancements across borders; ultimately bolstering hopes for individuals affected by fanconi anemia worldwide
Which are the best cities for fanconi anemia clinical trials?
When it comes to fanconi anemia clinical trials, several cities in the United States are at the forefront of research and innovation. Cincinnati, Ohio leads the way with 4 active trials investigating treatments such as Quercetin, Time-Restricted Feeding, and Peripheral blood stem cell therapy. Minneapolis, Minnesota follows closely behind with 3 ongoing studies focusing on factors like alcohol consumption and specific medications like FP-045 and G-CSF. Stanford, California also contributes significantly to fanconi anemia research with 3 active trials exploring potential breakthroughs like RP-L102 and JSP191. These cities offer individuals affected by fanconi anemia access to cutting-edge clinical trials that could provide new hope for effective treatments.
Which are the top treatments for fanconi anemia being explored in clinical trials?
Fanconi anemia is a rare genetic disorder, and clinical trials are actively exploring various treatment options. Prominent among these treatments are quercetin, RP-L102, time-restricted feeding, and JSP191. Quercetin, a dietary supplement, is being tested in two active trials for fanconi anemia since its first listing in 2012. Similarly, RP-L102 shows promise with two ongoing trials and three all-time trials since 2019. Another intriguing approach is time-restricted feeding with one active trial listed in 2022. Additionally, JSP191 has also entered the scene with one active trial following its introduction in 2021. These innovative avenues of research offer hope to individuals living with Fanconi anemia as scientists strive to find effective treatments for this challenging condition.
What are the most recent clinical trials for fanconi anemia?
Exciting advancements in clinical trials offer hope for individuals with Fanconi anemia, a rare genetic disorder. The most recent studies include FP-045 and JSP191, both currently in Phase 1 and Phase 2 stages of development. These innovative treatments became available on June 30, 2023, and December 7, 2021, respectively. Another notable trial is RP-L102, which reached Phase 2 and was made accessible to patients on July 15, 2020. Additionally, the drug Olaparib has shown promise during its Phase 2 trial that commenced on June 24th of the same year. These ongoing investigations highlight the dedication towards finding effective therapies for Fanconi anemia patients and provide encouragement for their well-being moving forward.
What fanconi anemia clinical trials were recently completed?
Recently completed clinical trials for Fanconi Anemia include:
- A trial investigating the efficacy of gene therapy, sponsored by Stanford University School of Medicine and completed in October 2021.
- A trial evaluating the use of hematopoietic stem cell transplantation, sponsored by Cincinnati Children's Hospital Medical Center and concluded in September 2021.
- A trial exploring a combination therapy approach, involving growth factors and steroids, sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which was completed in January 2021. These recent clinical trials represent important advancements in understanding and treating Fanconi Anemia, offering hope to patients affected by this rare genetic disorder.